2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriers
2019
Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction
Calcaterra SL, Bach P, Chadi A, Chadi N, Kimmel SD, Morford KL, Roy P, Samet JH. Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction. Journal Of General Internal Medicine 2019, 34: 1039-1042. PMID: 30729416, PMCID: PMC6544670, DOI: 10.1007/s11606-018-4801-3.Commentaries, Editorials and LettersConceptsOpioid use disorderLife-saving medicationsUse disordersOpioid use disorder treatmentIllicit opioid useUse of medicationsPharmacy-based modelsUse disorder treatmentOpioid useMethadone therapyOpioid epidemicOpioid overdoseOpioid addictionMedicationsMethadoneDisorder treatmentDisordersLogistical barriersTreatmentMajority of peopleMortalityMorbidityBuprenorphineLack accessOverdose